Manufacturing is key, otherwise an approval is mea
Post# of 147727
(Total Views: 601)
Posted On: 05/11/2020 3:55:59 AM
Manufacturing is key, otherwise an approval is meaningless (as Gilead experiences now)!!
Remdesivir availability is a major issue, while Gilead started at enough doses for 140,000 patients. More doses available next year! Huge risk, possibly made to be redundant/discarded...?
CytoDyn only have/had 40,000 doses Leronlimab to treat only 20,000 patients now. According to Nader there might be 600k doses available in June. Exactly at the same moment when the results of the phase 2 moderate become available?!
Manufacturing, distribution, availability....!!! That is the PR I am waiting for. The rest is just noise...
gf
Remdesivir availability is a major issue, while Gilead started at enough doses for 140,000 patients. More doses available next year! Huge risk, possibly made to be redundant/discarded...?
CytoDyn only have/had 40,000 doses Leronlimab to treat only 20,000 patients now. According to Nader there might be 600k doses available in June. Exactly at the same moment when the results of the phase 2 moderate become available?!
Manufacturing, distribution, availability....!!! That is the PR I am waiting for. The rest is just noise...
gf
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼